Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 CFR Part 314, Subpart D—FDA Action on Applications and Abbreviated Applications
21 CFR Part 314, Subpart D—FDA Action on Applications and Abbreviated Applications, “FDA Action on Applications and Abbreviated Applications”, is a CFR division of 21 CFR Part 314—Applications for FDA approval to market a new drug.
https://ontology.bommaritollc.com/id/01a0f094-b5f3-717b-b604-e7b462cd0e7c
Elsewhere
Facts
| adms:identifier | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 CFR Part 314, Subpart D |
| schema:legislationJurisdiction | |
| schema:legislationType | |
| schema:name | FDA Action on Applications and Abbreviated Applicationsen |
| skos:prefLabel | 21 CFR Part 314, Subpart D—FDA Action on Applications and Abbreviated Applicationsen |
Related
Parts (23)schema:isPartOf
- 21 CFR 314.100 Timeframes for reviewing applications and abbreviated applications.
- 21 CFR 314.101 Filing an NDA and receiving an ANDA.
- 21 CFR 314.102 Communications between FDA and applicants.
- 21 CFR 314.103 Dispute resolution.
- 21 CFR 314.104 Drugs with potential for abuse.
- 21 CFR 314.105 Approval of an NDA and an ANDA.
- 21 CFR 314.106 Foreign data.
- 21 CFR 314.107 Date of approval of a 505(b)(2) application or ANDA.
- 21 CFR 314.108 New drug product exclusivity.
- 21 CFR 314.110 Complete response letter to the applicant.
- 21 CFR 314.120
- 21 CFR 314.122 Submitting an abbreviated application for, or a 505(j)(2)(C) petition that relies on, a listed drug that is no longer marketed.
- 21 CFR 314.125 Refusal to approve an NDA.
- 21 CFR 314.126 Adequate and well-controlled studies.
- 21 CFR 314.127 Refusal to approve an ANDA.
- 21 CFR 314.150 Withdrawal of approval of an application or abbreviated application.
- 21 CFR 314.151 Withdrawal of approval of an abbreviated new drug application under section 505(j)(5) of the act.
- 21 CFR 314.152 Notice of withdrawal of approval of an application or abbreviated application for a new drug.
- 21 CFR 314.153 Suspension of approval of an abbreviated new drug application.
- 21 CFR 314.160 Approval of an application or abbreviated application for which approval was previously refused, suspended, or withdrawn.
- 21 CFR 314.161 Determination of reasons for voluntary withdrawal of a listed drug.
- 21 CFR 314.162 Removal of a drug product from the list.
- 21 CFR 314.170 Adulteration and misbranding of an approved drug.